Therapeutic Asset Ratings
210 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
TRIMIPRAMINE
Glioblastoma
Centre Hospitalier Universitaire Vaudois
P2
CC
(46)
Avutometinib
Glioblastoma
Institute of Cancer Research, United Kingdom
P1/2
CC
(46)
Defactinib
Glioblastoma
Institute of Cancer Research, United Kingdom
P1/2
CC
(46)
Oxodotreotide
Glioblastoma
Fundación de investigación HM
P1/2
CC
(46)
TN-TC11G
Glioblastoma
Grupo Español de Investigación en Neurooncología
P1/2
CC
(44)
n-803
Glioblastoma
ImmunityBio, Inc.
P2
CC
(42)
Egfrviii Car T Cells
Glioblastoma
Beijing Tsinghua Chang Gung Hospital
P1
CC
(42)
Gallium Maltolate
Glioblastoma
Medical College of Wisconsin
P1
CC
(42)
Aguix
Glioblastoma
Centre Jean Perrin
P1/2
CC
(41)
Allogeneic Genetically Modified Gamma-Delta T Cells
Glioblastoma
In8bio Inc.
P1/2
CC
(41)
Apg-157
Glioblastoma
Aveta Biomics, Inc.
P1/2
CC
(41)
Autologous Cd1C+ /Cd141+ Mydc
Glioblastoma
Universitair Ziekenhuis Brussel
P1/2
CC
(41)
Autologous Γδt Cells
Glioblastoma
In8bio Inc.
P1/2
CC
(41)
Ctx-009
Glioblastoma
Washington University School of Medicine
P1/2
CC
(41)
Ctx-471
Glioblastoma
Washington University School of Medicine
P1/2
CC
(41)
CYCLOHEXANEACETIC ACID, 1-(AMINOMETHYL)-
Glioblastoma
University of Zurich
P1/2
CC
(41)
DARATUMUMAB
Glioblastoma
West Virginia University
P1/2
CC
(41)
Dual-Target Antigen-Selected Car-Nk
Glioblastoma
Essen Biotech
P1/2
CC
(41)
EBNK-001
Glioblastoma
Essen Biotech
P1/2
CC
(41)
Eb-Select Single-Target Car-Nk Cells
Glioblastoma
Essen Biotech
P1/2
CC
(41)
il-15
Glioblastoma
Essen Biotech
P1/2
CC
(41)
Ino-5401
Glioblastoma
Inovio Pharmaceuticals
P1/2
CC
(41)
Ino-9012
Glioblastoma
Inovio Pharmaceuticals
P1/2
CC
(41)
Ivonescimab
Glioblastoma
M.D. Anderson Cancer Center
P1/2
CC
(41)
mt-125
Glioblastoma
Myosin Therapeutics Inc.
P1/2
CC
(41)
Showing 101 to 125 of 210 assets
Previous
Page 5 of 9
Next
